Sonnet BioTherapeutic News

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

GlobeNewswireFeb 26 09:00 ET

Express News | Sonnet Biotherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform Is Available for Drug Discovery Partnerships With Potential for Producing Multiple Pipeline Drug Candidates

ReutersFeb 19 08:35 ET

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

GlobeNewswireFeb 18 09:15 ET

Sonnet BioTherapeutic | 10-Q: Q1 2025 Earnings Report

SECFeb 13 16:22 ET · Announcements

Sonnet BioTherapeutics Reports Wider Q1 Net Loss, CFO Transition

Seeking AlphaFeb 13 08:42 ET

Express News | Sonnet Biotherapeutics Appoints Stephen Mcandrew, Ph.d. as Chief Business Officer

ReutersFeb 13 08:30 ET

Press Release: Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

Dow JonesFeb 13 08:30 ET

Sonnet BioTherapeutics Q1 EPS $(1.56) Misses $(1.39) Estimate

BenzingaFeb 13 08:28 ET

Express News | Sonnet BioTherapeutics CFO Resigns Effective Feb. 21, 2025; Co Names Donald Griffith As Successor

BenzingaFeb 13 08:17 ET

Sonnet BioTherapeutic | 8-K: Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

SECFeb 13 08:14 ET · Announcements

Sonnet BioTherapeutics Reports Positive Interim Results From Phase 1 SB101 Trial of SON-1010 and Advances Clinical Programs

Quiver QuantitativeFeb 13 08:13 ET

Sonnet BioTherapeutics Jay Cross Submitted His Resignation as Chief Fincl Officer, Effective Feb 21 >SONN

Dow JonesFeb 13 08:06 ET

Press Release: Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

Dow JonesFeb 13 08:00 ET

Express News | Sonnet Biotherapeutics Further Expands Global Intellectual Property Portfolio With Issuance of EU Patent for Fhab® Platform Technology

ReutersJan 28 09:17 ET

12 Health Care Stocks Moving In Thursday's Pre-Market Session

BenzingaJan 23 16:06 ET

Sonnet BioTherapeutics Has Been Granted European Patent Number EP3583125 Titled "ALBUMIN BINDING DOMAIN FUSION PROTEINS (FOR THE TREATMENT OF CANCER)".

BenzingaJan 22 15:58 ET

Express News | Sonnet BioTherapeutics Has Been Granted European Patent Number EP3583125 Titled "ALBUMIN BINDING DOMAIN FUSION PROTEINS (FOR THE TREATMENT OF CANCER)"

BenzingaJan 22 15:58 ET

Sonnet Expands Phase 1 SB101 Study Of SON-1010, Combining With Trabectedin In Advanced Soft-Tissue Sarcoma; Enrollment Of 18 Patients Expected By H1 2025; Topline Safety Data Due H2 2025; Monotherapy Suggested Clinical Benefit; Potential Phase 2 Study...

BenzingaJan 21 09:07 ET

Express News | Sonnet Biotherapeutics Holdings Inc - Topline Safety Data Expected in H2 2025

ReutersJan 21 09:05 ET

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 With Trabectedin in Certain Sarcomas

Sonnet BioTherapeuticJan 21 09:05 ET